Jordi Rubió-Casadevall, Beatriz Cirauqui Cirauqui, Javier Martinez Trufero, Maria Plana Serrahima, Almudena García Castaño, Alberto Carral Maseda, Lara Iglesias Docampo, Pedro Pérez Segura, Isaac Ceballos Lenza, Vanesa Gutiérrez Calderón, José Fuster Salvà, Carolina Pena Álvarez, Irene Hernandez, Edel Del Barco Morillo, Manuel Chaves Conde, Joaquina Martínez Galán, Marisa Durán Sánchez, Vanesa Quiroga, Eugenia Ortega, Ricard Mesia
OBJECTIVES: The aim of this study was to confirm the efficacy of the ERBITAX scheme (paclitaxel 80 mg/m2 weekly and cetuximab 400 mg/m2 loading dose, and then 250 mg/m2 weekly) as first-line treatment for patients with recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN) who are medically unfit for cisplatin-based (PT) chemotherapy. MATERIALS AND METHODS: This retrospective, non-interventional study involved 16 centers in Spain. Inclusion criteria were to have started receiving ERBITAX regimen from January 2012 to December 2018; histologically confirmed SCCHN including oral cavity, oropharynx, hypopharynx, and larynx; age ≥18 years; and platinum (PT) chemotherapy ineligibility due to performance status, comorbidities, high accumulated dose of PT, or PT refractoriness...
2023: Frontiers in Oncology